Riskpilot← Back to searchSign inGet full accessDuleipo AB
ABActiveOrg 5592428782Forskningsringen 19Retail sale of pharmaceutical products · NACE 4773Est. 20200 employees
Revenue 2024
SEK 533K
-80% vs 2023
EBITDA margin
140.5%
+656% vs 2023
Equity ratio
25.5%
Financial strength
Net profit 2024
SEK 600K
+1814% vs 2023
| Revenue | SEK 533K | -80% |
| EBITDA | SEK 749K | +656% |
| Net profit | SEK 600K | +1814% |
| Total assets | SEK 1,5M | +64% |
| Equity | SEK 387K | +282% |
| Employees | 0 | — |
Legal name
Duleipo AB
Org number
5592428782
Legal form
Aktiebolag
NACE code
4773 · Retail sale of pharmaceutical products
Founded
17 februari 2020
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva apoteksverksamhet i form av försäljning av egenvårdsprodukter (OTC-läkemedel) och därmed förenlig verksamhet. Bolaget skall också tillhandahålla konsulttjänster inom bemanning inom vårdsektorn.
Address
Forskningsringen 19
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 176 | 3 046 | 4 006 | 2 616 | 533 |
| Staff expenses | — | — | — | — | −0 |
| EBITDA | 1 | 143 | −76 | 99 | 749 |
| Depreciation & amort. | −0 | −134 | −134 | −134 | −33 |
| EBIT | 1 | 9 | −210 | −35 | 715 |
| Net financials | — | −2 | — | — | −0 |
| Profit before tax | 1 | 6 | −210 | −35 | 715 |
| Tax | −0 | −1 | −0 | −0 | −115 |
| Net profit | 1 | 5 | −210 | −35 | 600 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 610 | 1 940 | 1 748 | 923 | 1 515 |
| Equity | 26 | 31 | −178 | −213 | 387 |
| Long-term debt | 0 | 0 | 0 | 0 | — |
| Short-term debt | 1 584 | 1 909 | 1 926 | 1 136 | 1 129 |
| Total debt | 1 584 | 1 909 | 1 926 | 1 136 | 1 129 |
EBITDA margin
140.5%
This company
15.8%
Market median
+789% vs market
20202024
Equity ratio
25.5%
This company
38.2%
Market median
-33% vs market
20202024
Return on equity
155.2%
This company
18.4%
Market median
+743% vs market
20202024
Net profit margin
112.6%
This company
8.1%
Market median
+1290% vs market
20202024
Asset turnover
0.35×
This company
1.12×
Market median
-69% vs market
20202024
Debt / equity
2.92×
This company
0.62×
Market median
-371% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-02-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
WK Chief Executive Officer | Chief Executive Officer | 2025 |
| Former (1) | ||
LA Chief Executive Officer | Chief Executive Officer | 2020 – 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2025 | |
| Former (2) | ||
| Board of Directors | 2020 – 2025 | |
| Deputy Board Member | 2020 – 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Wael Smith AB
Duleipo AB Board members of Duleipo AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Leith Abdul Wahid Yassir | Chief Executive Officer | 0 companies |
| Wael Khedayier Yassir | Chief Executive Officer | 0 companies |
| Faouaz Jasim Badawi | Board of Directors | 0 companies |
| Lilas Yassir | Deputy Board Member | 0 companies |
| Maryam Badavi | Deputy Board Member | 0 companies |